Our findings suggested that multiple Akt targeting by drugs with different mechanism of action could represent a new promising treatment for T-cell acute lymphoblastic leukemia patients with PI3K/Akt/mTOR pathway hyperactivation. Here, MTOR is linked to T-cell acute lymphoblastic leukemia.